Lots to like here<p> I opened a position here Friday and have spent the past few days getting more familiar with this company. Up-listing to the NASDAQ is huge and will basically act as an IPO for this company. The problem is how they get there. It could be challenging for them to cross the $4 threshold, but I think a combination of great P1 AM data, initiation of P2 AM trial, first patients enrolled in the COVID trial, and sales numbers from Cortalex, has the potential to do the trick. They could also do a r/s, but I'd mufh prefer that they get there organically. There are ways for companies to up-list with a $2 and $3 pps if they meet other requirements, but a lot of the institutions can't buy stocks under $4 anyway, so it's kind of moot. </p> <p> It should be an exciting next few months. I'll probably continue to nibble away at these levels, as once they have up-listed we'll likely kiss single-digits goodbye.</p>